<SEC-DOCUMENT>0000903423-16-001337.txt : 20161107
<SEC-HEADER>0000903423-16-001337.hdr.sgml : 20161107
<ACCEPTANCE-DATETIME>20161107160852
ACCESSION NUMBER:		0000903423-16-001337
CONFORMED SUBMISSION TYPE:	SC 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20161107
DATE AS OF CHANGE:		20161107

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CRISPR Therapeutics AG
		CENTRAL INDEX KEY:			0001674416
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				473173478
		STATE OF INCORPORATION:			V8

	FILING VALUES:
		FORM TYPE:		SC 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-89674
		FILM NUMBER:		161978168

	BUSINESS ADDRESS:	
		STREET 1:		AESCHENVORSTADT 36
		CITY:			BASEL
		STATE:			V8
		ZIP:			4051
		BUSINESS PHONE:		6173154600

	MAIL ADDRESS:	
		STREET 1:		AESCHENVORSTADT 36
		CITY:			BASEL
		STATE:			V8
		ZIP:			4051

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GLAXOSMITHKLINE PLC
		CENTRAL INDEX KEY:			0001131399
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0

	FILING VALUES:
		FORM TYPE:		SC 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		980 GREAT WEST ROAD
		CITY:			BRENTFORD MIDDLESEX
		STATE:			X0
		ZIP:			TW8 9GS
		BUSINESS PHONE:		011442080475000

	MAIL ADDRESS:	
		STREET 1:		980 GREAT WEST ROAD
		CITY:			BRENTFORD MIDDLESEX
		STATE:			X0
		ZIP:			TW8 9GS
</SEC-HEADER>
<DOCUMENT>
<TYPE>SC 13D/A
<SEQUENCE>1
<FILENAME>glaxo-crspr13da1_1104.htm
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0">UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</P>

<P STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0">SCHEDULE 13D</P>

<P STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-bottom: 0; margin-left: 0">Under
the Securities Exchange Act of 1934</P>

<P STYLE="font: bold 9pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Amendment No. 1)*</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; border-bottom: black 0.5pt solid; text-align: center; margin-right: 0; margin-bottom: 0; margin-left: 0"><FONT STYLE="font-weight: normal">CRISPR
THERAPEUTICS AG</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-weight: normal">(Name
of Issuer) </FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; border-bottom: black 0.5pt solid; text-align: center; margin-right: 0; margin-bottom: 0; margin-left: 0"><FONT STYLE="font-weight: normal">Common
Shares, Par Value CHF 0.03</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-weight: normal">(Title
of Class of Securities)</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; border-bottom: black 0.5pt solid; text-align: center; margin-right: 0; margin-bottom: 0; margin-left: 0"><FONT STYLE="font-weight: normal">H17182108</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-weight: normal">(CUSIP
Number)</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; border-bottom: black 0.5pt solid; text-align: center"><FONT STYLE="font-weight: normal">Victoria
A. Whyte</FONT><BR>
<FONT STYLE="font-weight: normal">GlaxoSmithKline plc</FONT><BR>
<FONT STYLE="font-weight: normal">980 Great West Road</FONT><BR>
<FONT STYLE="font-weight: normal">Brentford, Middlesex TW8 9GS</FONT><BR>
<FONT STYLE="font-weight: normal">England</FONT><BR>
<FONT STYLE="font-weight: normal">Telephone: +44 (0)208 047 5000</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-weight: normal">(Name,
Address and Telephone Number of Person</FONT><BR>
<FONT STYLE="font-weight: normal">Authorized to Receive Notices and Communications)</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; border-bottom: black 0.5pt solid; text-align: center; margin-right: 0; margin-bottom: 0; margin-left: 0"><FONT STYLE="font-weight: normal">October
18, 2016</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-weight: normal">(Date
of Event which Requires Filing of this Statement)</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 10pt">If the filing person has previously filed a statement on Schedule
13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of &sect;&sect;240.13d-1(e),
240.13d-1(f) or 240.13d-1(g), check the following box. &#9744;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Note</B>: Schedules filed in paper format shall include
a signed original and five copies of the schedule, including all exhibits. See &sect;240.13d-7 for other parties to whom copies
are to be sent.</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 10pt"><SUP>*</SUP> The remainder of this cover page shall be filled
out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent
amendment containing information which would alter disclosures provided in a prior cover page.</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 10pt">The information required on the remainder of this cover page
shall not be deemed to be &quot;filed&quot; for the purpose of Section 18 of the Securities Exchange Act of 1934 (&quot;Act&quot;)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 12pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%">Cusip No. H17182108</TD>
    <TD STYLE="width: 34%; text-align: center; vertical-align: bottom">13 D/A1</TD>
    <TD STYLE="width: 33%; text-align: right; vertical-align: bottom">Page 2 of 4</TD></TR>
</TABLE>




<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 90%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 9pt">1.</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-size: 9pt">NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)</FONT><BR>
<BR>
<FONT STYLE="font-size: 9pt">GlaxoSmithKline plc</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 9pt">2.</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-size: 9pt">CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP</FONT><BR>
<FONT STYLE="font-size: 9pt">(see instructions)</FONT><BR>
<FONT STYLE="font-size: 9pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&#9744;</FONT><BR>
<FONT STYLE="font-size: 9pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&#9744;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 9pt">3.</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 9pt">SEC USE ONLY</FONT><BR>
<FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 9pt">4.</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 9pt">SOURCE OF FUNDS (see instructions)</FONT><BR>
<FONT STYLE="font-size: 9pt">&nbsp;</FONT><BR>
<FONT STYLE="font-size: 9pt">WC</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 9pt">5.</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 9pt">CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&#9746;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 9pt">6.</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 9pt">CITIZENSHIP OR PLACE OF ORGANIZATION</FONT><BR>
<FONT STYLE="font-size: 9pt">&nbsp;</FONT><BR>
<FONT STYLE="font-size: 9pt">England and Wales</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 13%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 81%">&nbsp;</TD></TR>
<TR>
    <TD ROWSPAN="4" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 9pt">NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 9pt">7.</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-size: 9pt">SOLE VOTING POWER</FONT><BR>
<FONT STYLE="font-size: 9pt">&nbsp;</FONT><BR>
<FONT STYLE="font-size: 9pt">3,250,627</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 9pt">8.</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-size: 9pt">SHARED VOTING POWER</FONT><BR>
<FONT STYLE="font-size: 9pt">&nbsp;</FONT><BR>
<FONT STYLE="font-size: 9pt">-0-</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 9pt">9.</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-size: 9pt">SOLE DISPOSITIVE POWER</FONT><BR>
<FONT STYLE="font-size: 9pt">&nbsp;</FONT><BR>
<FONT STYLE="font-size: 9pt">3,250,627</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 9pt">10.</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-size: 9pt">SHARED DISPOSITIVE POWER</FONT><BR>
<FONT STYLE="font-size: 9pt">&nbsp;</FONT><BR>
<FONT STYLE="font-size: 9pt">-0-</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 88%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 9pt">11.</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 9pt">AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON </FONT><BR>
<BR>
<FONT STYLE="font-size: 9pt">3,250,627 (1)</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 9pt">12.</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 12pt"><FONT STYLE="font-size: 9pt">CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES</FONT><BR>
<FONT STYLE="font-size: 9pt">(see instructions)&nbsp;&nbsp;&nbsp;&nbsp;&#9744;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 9pt">13.</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 9pt">PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) </FONT><BR>
<BR>
<FONT STYLE="font-size: 9pt">8.3% (2)</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 9pt">14.</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 9pt">TYPE OF REPORTING PERSON (see instructions) </FONT><BR>
<BR>
<FONT STYLE="font-size: 9pt">CO</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">Footnotes:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="5"><FONT STYLE="font-size: 9pt">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common Shares are held of record by S.R. One, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc.&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="5">
        <P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based upon 39,390,634 Common Shares outstanding, which includes
        39,360,634 Common Shares outstanding immediately after the Issuer&#8217;s IPO and the concurrent private placement, as reported
        in the Issuer&#8217;s prospectus (Form 424B4) filed with the SEC on October 19, 2016, and 30,000 Common Shares deliverable pursuant
        to the Stock Option.</P>
        <P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 12pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%">Cusip No. H17182108</TD>
    <TD STYLE="width: 34%; text-align: center; vertical-align: bottom">13 D/A1</TD>
    <TD STYLE="width: 33%; text-align: right; vertical-align: bottom">Page 3 of 4</TD></TR>
</TABLE><P STYLE="font: bold 9pt Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: bold 9pt Times New Roman, Times, Serif; margin: 0 0 10pt">Item 1.&nbsp;&nbsp;Security and Issuer.</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">This Amendment No. 1 to Schedule 13D amends
and supplements the statement on Schedule 13D originally filed on October 28, 2016 (the &#8220;Schedule 13D&#8221;) with respect
to the common shares, par value CHF 0.03 per share (the &#8220;Common Shares&#8221;), of CRISPR Therapeutics AG, a stock corporation
(<I>Aktiengesellschaft</I>) organized under the laws of Switzerland&nbsp;(the &#8220;Issuer&#8221;). GlaxoSmithKline plc is filing
this amendment solely to correct an inadvertent omission in Item 2 of the Schedule 13D. The Issuer&#8217;s principal executive
offices are located at Aeschenvorstadt 36, 4051 Basel, Switzerland. Unless otherwise indicated, each capitalized term used but
not defined herein shall have the meaning assigned to such term in the Schedule 13D.</P>

<P STYLE="font: bold 9pt Times New Roman, Times, Serif; margin: 0 0 10pt">Item 2.&nbsp;&nbsp;Identity and Background.&#9;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-weight: normal">The response set forth in
Item 2 of the Schedule 13D is hereby amended by deleting the last paragraph in its entirety and replacing it with the following:</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-weight: normal">On September 30, 2016, GlaxoSmithKline
plc agreed to a settlement with the SEC relating to an investigation into the commercial practices of certain subsidiaries of GlaxoSmithKline
plc in China. The SEC&#8217;s order found that GlaxoSmithKline plc violated the internal controls and books and records provisions
of the U.S. Foreign Corrupt Practices Act (the &#8220;FCPA&#8221;). GlaxoSmithKline plc consented to the order without admitting
or denying the findings, and agreed to pay a $20 million civil penalty. GlaxoSmithKline plc also agreed to provide status reports
to the SEC for the next two years on its remediation and implementation of anti-corruption compliance measures.</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0in">Other than as set forth above in this Item
2, during the last five years prior to the date hereof, neither GlaxoSmithKline plc nor, to the best knowledge of GlaxoSmithKline
plc, any of the other persons with respect to whom information is given in response to this Item 2 has been convicted in a criminal
proceeding or been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or
prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such
laws.</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 12pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%">Cusip No. H17182108</TD>
    <TD STYLE="width: 34%; text-align: center; vertical-align: bottom">13 D/A1</TD>
    <TD STYLE="width: 33%; text-align: right; vertical-align: bottom">Page 4  of 4</TD></TR>
</TABLE><P STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"></P><P STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"></P><P STYLE="color: red; font: 9pt Times New Roman, Times, Serif; border-top: black 1.5pt solid; margin-right: 0; margin-left: 0">&nbsp;</P>

<P STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0">SIGNATURE</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">After reasonable inquiry and to the best
of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.25in">Date: November 7, 2016</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 12pt 4in">GLAXOSMITHKLINE PLC</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 12pt 4in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 9pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 288pt"></TD><TD STYLE="width: 13.5pt">By:</TD><TD><U>&nbsp;&nbsp;/s/Victoria A. Whyte</U><BR>
                                         Victoria A. Whyte<BR>
                                         Authorized Signatory</TD></TR></TABLE>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
